Moreover, the recent use of nanobody technology to treat thrombotic thrombocytopenic purpura (TTP) may be of value, which binds to the A1 domain of the VWF, blocking its interaction with the platelet glycoprotein-Ib-IX-V receptor and therefore preventing platelet aggregation [149]. The gene discussed is VWF; the disease is thrombotic thrombocytopenic purpura.